$KYTX

LEO Pharma agreed to acquire worldwide rights to Tanabe Pharma’s dersimelagon for up to $435m. The late-stage oral drug completed Phase III, with an FDA NDA filed June 2026. Thermo Fisher and KYAN Technologies will collaborate on precision oncology using patient-derived tumoroids. Biogen’s felzartamab won China NMPA approval for multiple myeloma. Expedition Therapeutics raised $115m Series B for EXPD-101 COPD Phase II.

Kyverna Therapeutics, Inc. (KYTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potenti

The article reviews CAR-T companies developing therapies for autoimmune diseases. Kyverna Therapeutics’ miv-cel (CD19) is in phase 3 for stiff person syndrome, with a rolling FDA BLA filing started in May and completion expected by year end. Cabaletta’s rese-cel (CD19) is in phase 1/2 for SLE and other indications, with June myositis results. Cartesian’s Descartes-08 (BCMA, mRNA) is in phase 3 for myasthenia gravis.

BlackRock, Inc. filed a Schedule 13G reporting a 5.1% beneficial stake in Kyverna Therapeutics (KYTX), totaling 3,103,757 shares. The filing shows sole voting power of 3,069,290 shares and sole dispositive power of 3,103,757 shares, with no shared voting or dispositive authority.

Kyverna Therapeutics, Inc. (KYTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K 0001994702 false 0001994702 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,

The FDA outlined multiple initiatives to strengthen U.S. drug manufacturing and supply chain resilience, including its voluntary PreCheck Pilot Program, which on June 29, 2026 listed seven participating companies: Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin. It also described programs for faster clinical development, priority ANDA reviews, accelerated CNPV review, updated inspection compliance, and a proposed drug manufacturing registrati

Kyverna Therapeutics, Inc. (KYTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K 0001994702 false 0001994702 2026-07-08 2026-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8 ,

Kyverna Therapeutics (Nasdaq: KYTX) appointed Ritesh Srivastava as Chief Legal and Compliance Officer effective June 22, 2026, to support its transition toward commercialization of miv-cel (KYV-101). Srivastava joins from BPGbio and previously served at Spectrum Pharmaceuticals. The company also granted him an inducement option for 260,000 shares vesting over four years.

Bloomberg reports that Revolution Medicines’ daraxonrasib, a “molecular glue” drug, doubled median survival in aggressive pancreatic cancer from 6.7 to 13.2 months, with full phase 3 results expected at a Chicago conference. The success has spurred dealmaking and partnerships, including Monte Rosa’s potential $10B+ pacts with Novartis and Roche and J&J’s $3.05B Halda acquisition.

Kyverna Therapeutics reported that its Chief Financial Officer, Gregory S. Martini, was granted 325,000 stock options. These options have an exercise price of $8.54 per share and expire on May 18, 2036. The vesting schedule begins with one-quarter on May 18, 2027, with the remainder vesting monthly over the subsequent three years, contingent on his continuous service.